{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:06:31Z","timestamp":1784577991795,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ekir.2026.106571","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:10:29Z","timestamp":1777601429000},"page":"106571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paradoxical Hyponatremia on High-Dose Tolvaptan in ADPKD"],"prefix":"10.1016","volume":"11","author":[{"given":"Liliana Italia","family":"De Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Bianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiana","family":"Kola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Paolisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brambilla Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Farinone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Maiucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo Fernando","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Livia","family":"Lanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Sciarrone Alibrandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106571_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106571_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"TEMPO. 4 trial investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106571_bib3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106571_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106571_bib5","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3390\/ijms25042088","article-title":"Long-term effects of tolvaptan in autosomal dominant polycystic kidney disease: predictors of treatment response and safety over 6 years of continuous therapy","volume":"25","author":"Yamazaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106571_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ekir.2024.01.020","article-title":"Prospective study on individualized dose adjustment of tolvaptan based on urinary osmolality in patients with ADPKD","volume":"9","author":"Roca Oporto","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106571_bib7","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.ekir.2025.03.059","article-title":"Refining tolvaptan dosing in ADPKD: the role of urinary biomarkers in enhancing outcomes","volume":"10","author":"De Rosa","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.ekir.2026.106571_bib8","first-page":"6","article-title":"The management of patients with adult autosomal dominant polycystic kidney disease (ADPKD) requires a multidisciplinary approach","volume":"40","author":"Bucci","year":"2023","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.ekir.2026.106571_bib9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926028032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:00:56Z","timestamp":1784577656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926028032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2468024926028032"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106571","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradoxical Hyponatremia on High-Dose Tolvaptan in ADPKD","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106571"}}